Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK   US58933Y1055

MERCK & CO., INC. (MRK)

106
Delayed Quote. Delayed Nyse - 04/22 04:01:50 pm
57.77 USD   +0.91%
1d ago Novartis, Valeant bids herald new deal-making era for pharma
1d agoDJGlaxo Exits Cancer Drugs
2d ago AstraZeneca cancer pipeline seen as draw for Pfizer
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

06/13/2012 | 08:52am US/Eastern
Recommend:
0
   By Victoria Stilwell 
 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com

Recommend :
0
React to this article
Latest news on MERCK & CO., INC.
1d ago Novartis, Valeant bids herald new deal-making era for pharma
1d agoDJGlaxo Exits Cancer Drugs
2d ago AstraZeneca cancer pipeline seen as draw for Pfizer
6d ago MERCK : FDA Approves Merck’s RAGWITEK™ (Short Ragweed Pollen Allerge..
6d ago MERCK : FDA OKs Merck tablet to reduce ragweed allergies
6d agoDJEuropean Regulator Warns of More Drug Tampering
6d ago MERCK : Study Findings from Merck & Company Provide New Insights into Connective..
7d ago MERCK : Findings from Merck & Company in the Area of Adenosine Therapy Described
7d ago Reckitt leans towards pharmaceuticals spin-off
04/15 Cargill expects flour merger with ConAgra to be finalized in 6-8 weeks
Advertisement
Chart
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
Merck _ Co., Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF